NilotinibMeSH concept

https://www.has-sante.fr/portail/jcms/c_2883466/fr/tasigna
2018
false
true
false
France
nilotinib
treatment outcome
insurance, health, reimbursement
nilotinib
evaluation of the transparency committee
nilotinib hydrochloride hydrate
nilotinib
pyrimidines
nilotinib
pyrimidines

---
https://www.has-sante.fr/portail/jcms/c_2853363/fr/tasigna
2018
false
France
French
English
evaluation of the transparency committee
child
nilotinib
Tyrosine Kinase Inhibitors
leukemia, myeloid, chronic-phase
nilotinib
administration, oral
nilotinib
insurance, health, reimbursement
antineoplastic agents
protein-tyrosine kinases
pyrimidines

---
In : Bulletin du Cancer Volume 103, Issue 2, February 2016, Pages 180–189 - Open Access
http://www.sciencedirect.com/science/article/pii/S0007455115003689
2016
false
false
false
Netherlands
French
journal article
nilotinib
nilotinib
protein-tyrosine kinases
leukemia, myeloid, chronic-phase
cardiovascular diseases
risk factors
risk assessment
cardiovascular diseases
practice guideline
Tyrosine Kinase Inhibitors
nilotinib
nilotinib
pyrimidines
pyrimidines

---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-BCR-ABL-Imatinib-Dasatinib-Nilotinib-Bosutinib-Ponatinib-Medicament-ciblant-JAK-Ruxolitinib-Anticancereux-par-voie-orale-informer-prevenir-et-gerer-leurs-effets-indesirables
2016
false
false
false
France
French
practice guideline
antineoplastic agents
administration, oral
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
information dissemination
patient education as topic
drug interactions
Dasatinib
Imatinib Mesylate
fusion proteins, bcr-abl
protein kinase inhibitors
dasatinib
imatinib
nilotinib
nilotinib
bosutinib
ponatinib
ruxolitinib
janus kinases
ponatinib
ruxolitinib
bosutinib
continuity of patient care
pregnancy
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
aniline compounds
nitriles
quinolines
imidazoles
pyridazines
pyrimidines
pyrazoles

---
BCR-ABL Tyrosine Kinase Inhibitors [GLEEVEC (imatinib mesylate), TASIGNA (nilotinib), BOSULIF (bosutinib), SPRYCEL (dasatinib), ICLUSIG (ponatinib hydrochloride)] - Risk of Hepatitis B Reactivation
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58222a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
fusion proteins, bcr-abl
protein kinase inhibitors
Imatinib Mesylate
risk
hepatitis b virus
imatinib
nilotinib
nilotinib
bosutinib
bosutinib
Dasatinib
dasatinib
ponatinib hydrochloride
ponatinib
Tyrosine Kinase Inhibitor
Hepatitis B reactivation
guidelines for drug use
continuity of patient care
mass screening
hepatitis B
hepatitis B
Tyrosine Kinase Inhibitors
nilotinib
ponatinib
pyrimidines
imidazoles
pyridazines
aniline compounds
nitriles
quinolines

---
http://www.e-cancer.fr/content/download/126025/1524695/file/Médicaments%20ciblant%20BCR-ABL.pdf
2015
false
false
false
France
French
practice guideline
guidelines for drug use
administration, oral
antineoplastic agents
Drug-Related side effects and adverse reactions
imatinib
dasatinib
nilotinib
nilotinib
bosutinib
bosutinib
ponatinib
ponatinib
protein kinase inhibitors
ruxolitinib
ruxolitinib
janus kinases
information dissemination
continuity of patient care
hospital-physician relations
hospital-patient relations
physician-patient relations
drug interactions
pregnancy
protein-tyrosine kinases
Tyrosine Kinase Inhibitor
Dasatinib
Imatinib Mesylate
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
pyrazoles
aniline compounds
nitriles
quinolines
imidazoles
pyridazines

---
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/26651a-fra.php
false
France
French
canada
protein kinase inhibitors
leukemia, myelogenous, chronic, bcr-abl positive
nilotinib
antineoplastic agents
pharmacovigilance note
atherosclerosis
nilotinib

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00145
2011
false
false
false
Canada
drug information
nilotinib
capsules
nilotinib hydrochloride hydrate

---